Value of drug level testing and antibody assays in optimising biological therapy

por Vermeire, Séverine, Gils, Ann
Publicado 2013

JAK Inhibitors: Back to Small Molecules for the Treatment of IBD

por Panés, Julian, Vermeire, Severine
Publicado 2020

Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview

por Pouillon, Lieven, Vermeire, Séverine, Bossuyt, Peter
Publicado 2019

Let Food Be Thy Medicine—Its Role in Crohn’s Disease

por Wellens, Judith, Vermeire, Séverine, Sabino, João
Publicado 2021

Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises

por Alsoud, Dahham, Vermeire, Séverine, Verstockt, Bram
Publicado 2022

Adalimumab in Crohn’s disease

por Van Assche, Gert, Vermeire, Séverine, Rutgeerts, Paul
Publicado 2007

Vaccination and infection prevention in inflammatory bowel disease

por Vermeire, Severine, Van Assche, Gert, Rutgeerts, Paul
Publicado 2010

Infliximab: the evidence for its place in therapy in ulcerative colitis

por Van Assche, Gert, Vermeire, Séverine, Rutgeerts, Paul
Publicado 2007

Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer

por Jauregui-Amezaga, Aranzazu, Vermeire, Séverine, Prenen, Hans
Publicado 2016

Advanced Imaging in Gastrointestinal Endoscopy: A Literature Review of the Current State of the Art

por Sinonquel, Pieter, Vermeire, Séverine, Maes, Frederik, Bisschops, Raf
Publicado 2022

New biologics and small molecules in inflammatory bowel disease: an update

por Sabino, João, Verstockt, Bram, Vermeire, Séverine, Ferrante, Marc
Publicado 2019

How to place the duality of specific MMP-9 inhibition for treatment of inflammatory bowel diseases into clinical opportunities?

por Opdenakker, Ghislain, Vermeire, Séverine, Abu El-Asrar, Ahmed
Publicado 2022

New treatment options for inflammatory bowel diseases

por Verstockt, Bram, Ferrante, Marc, Vermeire, Séverine, Van Assche, Gert
Publicado 2018

GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD

por Dierckx, Tim, Verstockt, Bram, Vermeire, Séverine, van Weyenbergh, Johan
Publicado 2019

Immunogenicity of biologics in inflammatory bowel disease

por Vermeire, Séverine, Gils, Ann, Accossato, Paola, Lula, Sadiq, Marren, Amy
Publicado 2018

Short chain fatty acids and its producing organisms: An overlooked therapy for IBD?

por Deleu, Sara, Machiels, Kathleen, Raes, Jeroen, Verbeke, Kristin, Vermeire, Séverine
Publicado 2021

Computational Biology and Machine Learning Approaches to Understand Mechanistic Microbiome-Host Interactions

por Sudhakar, Padhmanand, Machiels, Kathleen, Verstockt, Bram, Korcsmaros, Tamas, Vermeire, Séverine
Publicado 2021

Personalized Dietary Regimens for Inflammatory Bowel Disease: Current Knowledge and Future Perspectives

por Wellens, Judith, Vissers, Eva, Matthys, Christophe, Vermeire, Séverine, Sabino, João
Publicado 2023

Comparisons of gut microbiota profiles in wild-type and gelatinase B/matrix metalloproteinase-9-deficient mice in acute DSS-induced colitis

por de Bruyn, Magali, Sabino, João, Vandeputte, Doris, Vermeire, Séverine, Raes, Jeroen, Opdenakker, Ghislain
Publicado 2018

Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn’s di...

por Van den Berghe, Nathalie, Alsoud, Dahham, Verstockt, Bram, Vermeire, Séverine, Declerck, Paul, Thomas, Debby
Publicado 2023